Endogenous FGF21 serum levels, however, are increased during obesity-related diseases, suggesting the development of FGF21 resistance during obesity and thereby lowering FGF21 efficacy. Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.